Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

fically inhibit the production of VLA-4 could significantly reduce disease activity in RRMS patients as early as 8 weeks. The level of efficacy achieved by ATL/TV1102 is very promising particularly when considering the short duration of dosing within the trial. As an antisense drug ATL/TV1102 will have a different, potentially preferable, safety profile to other drugs that target VLA-4 and therefore presents an exciting future treatment option for RRMS patients."

Mark Diamond, Chief Executive Officer of Antisense Therapeutics, said, "We are delighted to have our ATL/TV1102 Phase IIa trial results presented at such an important scientific meeting on MS. The development of ATL/TV1102 as an MS treatment continues with our partner Teva Pharmaceutical Industries (Teva) and we look forward to the prospect of Teva reporting on ATL/TV1102's future clinical progress. Importantly, the demonstration of significant disease activity with ATL/TV1102 in MS points to the potential of ATL/TV1102 in other disease settings such as autoimmune, inflammation and cancer. It also provides important validation for the application of second-generation antisense drugs outside of cardiovascular and metabolic diseases such as high cholesterol and diabetes where there has been success to date. We believe our results provide important substantiation for the broader clinical application of the second-generation technology."

"We are very encouraged by the data. Not only do they represent promising results for patients with MS, but they also evidence the significant progress we are making in demonstrating the effectiveness, efficiency and the breadth of opportunity of our antisense platform. It's another disease and another tissue where we have great proof-of-concept for antisense drugs," said Stanley Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis. "ATL/TV1102 and ATL's strategic relationship with Teva to move the drug forward further validates our business strategy.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Packaging Coordinators, Inc. (PCI) is pleased to ... Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is headquartered ... United Kingdom and operates regional ... and Tokyo , Japan. Penn Pharma offers ... Commercial dosage form manufacturing, as well as Clinical Packaging, ...
(Date:7/30/2014)...  Hospira, Inc. (NYSE: HSP ), ... infusion technologies, today reported results for the second ... the quarter were $1.1 billion and adjusted* diluted ... specified items as described later in this press ... Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2014 ...
(Date:7/30/2014)... , July 30, 2014  PDL BioPharma, Inc. (PDL) ... management will participate in the Jefferies 2014 Boston Healthcare ... Massachusetts. The conference will occur on August 6, 2014 and ... Inc. PDL BioPharma manages a portfolio of ... et al. antibody humanization patents and license agreements with ...
Breaking Medicine Technology:PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
... Bionovo, Inc. (Nasdaq: BNVI ), a ... safe and effective treatments for women,s health and cancer, ... 3 pivotal clinical trial evaluating the safety and efficacy ... of postmenopausal women for the treatment of menopausal hot ...
... The Pennsylvania State Police will accept unwanted, expired and ... of National Prescription Drug Take Back Day. ... to raise awareness of the problem with prescription-drug abuse ... unused, unwanted and expired prescription drugs," State Police Commissioner ...
Cached Medicine Technology:Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 2Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 3Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 4
(Date:7/30/2014)... Ticket Down is a reputable source for affordable ... on Saturday, August 2nd. Two of the most popular ... on American soil on Aug. 2 when Manchester United and Real ... home of the University of Michigan is also known as Michigan ... of American sports and has also hosted numerous other monumental events ...
(Date:7/30/2014)... happen in an instant: A small child pulls up on ... injured when the furniture tips over. "Every parent or ... and imagine what could tip over, fall off walls and ... a reality," Dr. Alex Rosenau, president of the American College ... Between 2009 and 2011, roughly 43,000 people ended up in ...
(Date:7/30/2014)... Imprivata ® (NYSE: IMPR), ... secure communications solutions for the healthcare industry, today ... most widely selected single sign-on (SSO) solution amongst ... medical records (EMR) systems with a 51 percent ... in the last 12 months), according to HIMSS ...
(Date:7/30/2014)... Louisville, KY (PRWEB) July 30, 2014 ... is pleased to announce the launch of its ... free, online resource for medical professionals and equipment vendors. ... trade shows and conventions in the United States and ... on the calendar, and that number is always growing. ...
(Date:7/30/2014)... Angeles, CA (PRWEB) July 30, 2014 ... the Chao Pinhole Surgical Technique®, the revolutionary minimally invasive ... Dennis Shanelec, considered by many of his peers to ... special guest speaker at a recent Chao Pinhole Surgical ... Alhambra, CA. Dr. Shanelec is the recipient of the ...
Breaking Medicine News(10 mins):Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 2Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 3Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 4Health News:Tip-Over Furniture Can Kill Kids 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2
... informed, survey finds , TUESDAY, May 4 (HealthDay News) ... the United States, yet a new survey of 1,000 ... their local hospitals offer specialized treatment for stroke. , ... stroke-certified hospitals," Dr. Ralph Sacco, president-elect of the American ...
... ... announced today that it is adding a Certificate of Learning in Medical ... which is completed 100% online, is designed for those students who want ... prepares students for the American Health Information Management Association’s (AHIMA) Certified Coding ...
... ... Myeexpert in partnership with Strategic Insight Publishing, took a step further with the ... Living and Relationships. , ... May 4, 2010 -- Quoting verses from the book, the Founder and CEO of Myeexpert, ...
... ... dental marketing services and expert author, recently published his 1st article for LIVESTRONG.COM. , ... New York, NY (Vocus) May 4, ... his first article for LIVESTRONG.COM. His articles will focus on a variety of ...
... don,t get enough sleep may gain more than some ... friends. They also may gain weight, according to research ... Societies (PAS) annual meeting in Vancouver, British Columbia, Canada. ... and weight issues, particularly in young children. However, this ...
... ... hopes to shed light on ,Skin Cancer Awareness Month through annual Baby Skinz giveaway. ... Sonora, CA (PRWEB) -- UV ... an order this May in honor of National Skin Cancer Awareness Month. UV Skinz, one ...
Cached Medicine News:Health News:Many Unaware of Local Stroke Centers 2Health News:Grantham University Announces New Certificate of Learning in Medical Coding and Billing 2Health News:Grantham University Announces New Certificate of Learning in Medical Coding and Billing 3Health News:“You Are Very Pretty”, Says Myeexpert As It Releases A Book, Poetic Expressions, Dedicated To The Beauty of Women. 2Health News:Dental Practice Marketing Specialist Publishes 1st Article for LIVESTRONG.COM 2Health News:Less sleep may add up to more pounds in adolescents 2Health News:Save Baby's Skin with Free Baby UV Skinz 2Health News:Save Baby's Skin with Free Baby UV Skinz 3
... new Platinum 10 concentrator. The Platinum 10 ... you have come to expect from the ... attractive alternative to liquid systems. The Platinum ... LPM for high flow patients, and has ...
... Portable Oxygen Concentrator is the most compact, ... 10 lbs (4.5 kg), this unit was ... highly active oxygen patient., ,Operating as ... technologies of both an oxygen concentrator and ...
OCD-3000 pnuematic conserving regulator....
... liters out of your five-liter concentrators. , ... your high-flow patients! , ,In many ... standard conservers, because they extend oxygen duration by ... a patient. However, they do not require ...
Medicine Products: